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Purpose: Elevated donor-derived cell-free DNA (dd-cfDNA) has been observed in transplant patients 
undergoing acute rejection, but the relationship between dd-cfDNA and long term outcomes has not previously 
been studied. In this exploratory study, serially measured dd.cfDNA from heart transplant patients is used for 
predict 3-year patient adverse outcomes of death, retransplantation, hemodynamic compromise or graft 
dysfunction. 
 
Methods: cfDNA was extracted from 166 plasma samples representing 48 patients from the CARGO II 
observational study and dd-cfDNA was quantified using a targeted NGS assay. For each patient, the median and 
maximum of serial dd-cfDNA scores were calculated. The summarized scores for patients with long-term 
adverse outcomes and patients without adverse outcomes were compared via two-sample testing and AUC-ROC 
analysis. Within-patient variability of dd-cfDNA scores for patients who had at least 4 scores was also computed 
(17 patients total). 
 
Results: Eight of the 48 patients (40 samples) had a adverse outcome and serial dd-cfDNA measurements. 
Patients were 49 ± 13 years old, 79% male and 96% caucasian, with no statistically significant difference 
between groups. Within-patient median dd-cfDNA was significantly correlated with outcome (p = 0.02, AUC 
77%, 95% CI 59%-92%) but within-patient maximum was not (p = 0.11, AUC 68%). Analysis using all dd-
cfDNA results from every patient was also not significantly correlated with outcomes, p = 0.09. The AUC for 
predicting long term outcomes in the CARGO II dataset using variability of gene expression profiling scores was 
72%, dd-cfDNA variability was noticeably increased in four patients who an adverse outcome and had four 
serial AlloSure scores when compared to 13 patients who did not have an adverse outcome. 
 
Conclusion: Median dd-cfDNA score is correlated to long-term outcome. This result suggests that dd-cfDNA 
merits further investigation as a prognostic marker of long-term risk in heart transplant patients. 
 
